Maraviroc (MVC, 88), as shown in Figure 18, a selective CCR5 (C-C Motif Chemokine Receptor 5) antagonist with broad-spectrum antiretroviral efficacy that has been used in treatment of HIV-1 infection, was recently validated to be an attractive LRA by inducing NF-κB activation as a result of specific binding of CCR5, whether used alone or in combination with PKC activator bryostatin-1 [97]. The gene discussed is NFKB1; the disease is HIV-1 infection.